Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
San Francisco sues 10 companies that make ultraprocessed food - 2Starship success, a private moon landing and more: The top 10 spaceflight stories of 2025
- 3UK, Canada, Germany, others condemn Israel's West Bank settlement plan
- 4The Main 10 Natural life Protection Associations
- 5Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
- Belarusian parliament passes a bill to crack down on LGBTQ+ rights
- Energy security rifts widen in Europe
- A Manual for SUVs with Less Noteworthy Gas Mileage
- This widow influencer is using jokes to cope after her husband's death. It's OK if people don't get it.
- I’m a neuroscientist who taught rats to drive − their joy suggests how anticipating fun can enrich human life
- The Significance of Prenuptial Arrangements in Separation Procedures
- Los Angeles County sees significant uptick in norovirus cases, officials say
- Novo Nordisk cuts Wegovy price in South Africa for a second time
- NASA's Artemis 2 astronauts are cruising to the moon. So why are they doing CPR tests today?
